Abediterol/AZD 7594

Drug Profile

Abediterol/AZD 7594

Alternative Names: Abediterol/AZ13189620; AZD7594/abediterol

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 21 Dec 2016 Chemical structure information added
  • 28 Nov 2016 Preclinical trials in Asthma and Chronic Obstructive Pulmonary Disease in Germany before November 2016 (Inhalation)
  • 28 Nov 2016 AstraZeneca plans a phase I trial for Chronic Obstructive Pulmonary Disease and Asthma (In voulnteers) (NCT02967159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top